New hope for tough leukemia: three-drug combo targets relapsed B-ALL
NCT ID NCT05657652
First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 14 times
Summary
This study tests a combination of three drugs (venetoclax, cladribine, and low-dose cytarabine) in 36 people aged 15-70 with relapsed or treatment-resistant Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. The goal is to see how many patients achieve complete remission. This is not a cure, but aims to control the disease when standard treatments have failed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.